Onconic Therapeutics

Total Valuation

Onconic Therapeutics carries a market capitalization of 192.45B, placing it among publicly traded companies globally. Its enterprise value stands at 876.81B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Valuation Ratios

Onconic Therapeutics trades at a trailing price-to-earnings ratio of 45.95. The price-to-sales ratio is 13.90, and the price-to-book ratio stands at 16.81.

Enterprise Valuation

On an enterprise value basis, Onconic Therapeutics trades at an EV/EBITDA multiple of 56.11 and an EV/FCF ratio of 63.63. The EV/Sales ratio of 13.05 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 56.11 provides insight into valuation relative to core operating earnings.

Financial Position

Onconic Therapeutics maintains a current ratio of 9.48, meaning it holds 9.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.15, indicating conservative leverage, while an interest coverage ratio of 1,661.53 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Onconic Therapeutics posts a return on equity of 55.11 and a return on invested capital of 22.57.

Taxes

Over the trailing twelve months, Onconic Therapeutics has paid 16.83M in income taxes, reflecting an effective tax rate of 0.09.

Stock Price Statistics

Onconic Therapeutics's stock has declined approximately -17.58294% over the past 52 weeks. The 50-day moving average sits at 21,269.40, while the 200-day moving average is 17,922.29.

Income Statement

Over the trailing twelve months, Onconic Therapeutics generated 67.20B in revenue and converted that into 20.33B in net income, yielding earnings per share of 453.73. EBITDA reached 15.63B, while operating income came in at 15.63B.

Balance Sheet

Onconic Therapeutics holds 57.31B in cash and equivalents against 115.43M in total debt, resulting in a net debt position of -51.77B. Total book value stands at 55.55B, with working capital of 67.77B providing operational flexibility.

Cash Flow

Onconic Therapeutics produced 13.59B in operating cash flow over the past twelve months. After subtracting -182.35M in capital expenditures, free cash flow totaled 13.41B - equivalent to 302.13 per share.

Margins

Onconic Therapeutics operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 23.25 and net profit margin of 30.25 provide insight into operational efficiency.

Dividends & Yields

Scores

Onconic Therapeutics posts an Altman Z-Score of 72.32, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.